Nicholas J. Casacchia

Nicholas J. Casacchia

Auto-generated profile, based on publicly available information

Nicholas J. Casacchia

Center for Value-Based Care Research, Department of Internal Medicine and Geriatrics, Primary Care Institute, Cleveland Clinic, Cleveland, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2022 in Academic Pediatrics
Verified
Journal Article
Closed access
KCKathryn S. Cain
Kathryn S. Cain
SMStephanie C. Meyer
Stephanie C. Meyer
ECElaina Cummer
Elaina Cummer
KPKishan K. Patel
Kishan K. Patel
NCNicholas J. Casacchia
Nicholas J. Casacchia
CBCallie Brown
Callie Brown

16 September 2025 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
HGHamlet Gasoyan
Hamlet Gasoyan
MAMohammad Hesam Alavi
Mohammad Hesam Alavi
AZAlexander Zajichek
Alexander Zajichek
NCNicholas J. Casacchia
Nicholas J. Casacchia
AJAbdullah Al Jabri
Abdullah Al Jabri
AAAli Aminian
Ali Aminian

1 May 2024 in JCO Oncology Practice
Verified
Journal Article
Closed access
HGHamlet Gasoyan
Hamlet Gasoyan
FAFaiz Anwwer
Faiz Anwwer
NCNicholas J. Casacchia
Nicholas J. Casacchia
JKJeffrey D. Kovach
Jeffrey D. Kovach
JVJason Valent
Jason Valent
MRMichael B. Rothberg
Michael B. Rothberg
PURPOSE: Little is known about the role of social determinants of health (SDOH) in the utilization of novel treatments among patients with newly diagnosed multiple myeloma (NDMM). METHODS: This retrospective cohort study used Taussig Cancer Center's Myeloma Patient Registry to identify adults with NDMM between January 1, 2017, and December 31, 2021. Electronic health records data captured treatment with (1) triplet or quadruplet regimen and (2) lenalidomide during the first year after NDMM, and (3) stem-cell transplant (SCT) through December 31, 2022. Multivariable logistic regression models examined associations of demographic/clinical characteristics and SDOH with care patterns. RESULTS: We identified 569 patients with median age at diagnosis of 66 years (IQR, 59-73); 55% were male, 76% White, 23% Black, 1.1% other races, insured by Medicare (51%), private payer (38%), Medicaid (8.3%), and self-pay/other (1.8%). In the multivariable models, self-pay/other payers (adjusted odds ratio [AOR], 0.15 [95% CI, 0.03 to 0.54]) was associated with lower odds of triplet or quadruplet regimen, compared with Medicare. Private insurance (AOR, 0.48 [95% CI, 0.27 to 0.86]) and self-pay/other payers (AOR, 0.16 [95% CI, 0.04 to 0.74]) had lower odds of lenalidomide. Black patients ( v White; AOR, 0.47 [95% CI, 0.26 to 0.85]) and patients treated at regional hospitals ( v Taussig Cancer Center; AOR, 0.27 [95% CI, 0.12 to 0.57]) had lower odds of SCT. The odds of receiving triplet or quadruplet regimen, lenalidomide, and SCT also varied by the year of NDMM. CONCLUSION: Care for NDMM varied based on race, insurance type, year of diagnosis, and treatment facility. It may be useful to examine the impact of insurance-related characteristics and recent policy initiatives on care disparities.

17 October 2024 in American Journal of Preventive Medicine
Verified
Journal Article
Closed access
JPJoseph Carter Powers
Joseph Carter Powers
MRMichael B. Rothberg
Michael B. Rothberg
JKJeffrey D. Kovach
Jeffrey D. Kovach
NCNicholas J. Casacchia
Nicholas J. Casacchia
ESElizabeth Stanley
Elizabeth Stanley
KMKathryn A. Martinez
Kathryn A. Martinez

23 August 2024 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
HGHamlet Gasoyan
Hamlet Gasoyan
FAFaiz Anwwer
Faiz Anwwer
JKJeffrey D. Kovach
Jeffrey D. Kovach
NCNicholas J. Casacchia
Nicholas J. Casacchia
MWMing Wang
Ming Wang
MRMichael B. Rothberg
Michael B. Rothberg
This retrospective cohort study used Taussig Cancer Center’s Myeloma Patient Registry to identify adults with multiple myeloma diagnosed between January 2017-December 2021. Electronic health records data captured time from diagnosis to initial prescription fill for oral antimyeloma medications and initiation of facility administered or oral antimyeloma treatment. We identified 720 patients with a mean age at diagnosis of 67 years ±11; 55% were male, 77% White, 22% Black, 1% other races, covered by private insurance (36%), traditional Medicare (29%), Medicare Advantage (25%), and Medicaid (8.3%). Over a third of patients (37%) resided in an area in the most disadvantaged area deprivation index (ADI) quartile. The median available follow-up was 765 days. Seventy-five percent of the cohort filled an oral antimyeloma medication prescription (excluding corticosteroids), with a median time to fill of 28 days (IQR, 15–61). In the multivariable Cox regression model, Black race (vs. White, adjusted hazard ratio [aHR], 0.61, 95% CI, 0.42–0.87), older age at diagnosis (aHR per 1 year, 0.97, 95% CI, 0.95–0.98), diagnosis during an inpatient admission (aHR, 0.63, 95% CI, 0.43–0.92), and estimated glomerular filtration rate ≤29 ml/min/1.73 m2 (vs. ≥60, aHR, 0.46, 95% CI, 0.29–0.73) were negatively associated with prescription fill for oral antimyeloma medication at 30 days, while insurance type and ADI were not significant predictors.

7 October 2026 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
HGHamlet Gasoyan
Hamlet Gasoyan
SRShahzad Raza
Shahzad Raza
MRMichael B. Rothberg
Michael B. Rothberg
JKJeffrey D. Kovach
Jeffrey D. Kovach
NCNicholas J. Casacchia
Nicholas J. Casacchia
FAFaiz Anwwer
Faiz Anwwer